Edition:
India

Capricor Therapeutics Inc (CAPR.OQ)

CAPR.OQ on NASDAQ Stock Exchange Capital Market

1.39USD
10:34pm IST
Change (% chg)

$-0.01 (-0.71%)
Prev Close
$1.40
Open
$1.38
Day's High
$1.42
Day's Low
$1.38
Volume
37,844
Avg. Vol
45,164
52-wk High
$4.25
52-wk Low
$0.63

Latest Key Developments (Source: Significant Developments)

Capricor Therapeutics Appoints Anthony Bergmann As CFO, Eff Jan 1, 2018 - SEC Filing
Saturday, 23 Dec 2017 

Dec 22 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS INC SAYS HAS APPOINTED ANTHONY BERGMANN AS CHIEF FINANCIAL OFFICER, EFFECTIVE JANUARY 1, 2018 - SEC FILING.CAPRICOR THERAPEUTICS INC - ON DEC 20, LELAND GERSHELL GAVE NOTICE OF HIS RESIGNATION AS CHIEF FINANCIAL OFFICER OF COMPANY, EFFECTIVE JANUARY 1, 2018.  Full Article

Capricor & California Institute For Regenerative Medicine​ Entered Into Amendment 3 To CIRM Notice Loan Award
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR SAYS ‍ON DEC 11, CO, CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE​ ENTERED INTO AMENDMENT NO. 3 TO CIRM NOTICE OF LOAN AWARD - SEC FILING.CAPRICOR SAYS PURSUANT TO AMENDMENT, TOTAL LOAN BALANCE UNDER LOAN AWARD FORGIVEN BY CIRM, TERMINATING UNIT, CO'S OBLIGATION TO REPAY LOAN BALANCE​.CAPRICOR - ‍DECISION TO TERMINATE LOAN AWARD AND FORGIVE LOAN BALANCE WAS DUE TO ABANDONMENT OF ALLSTAR PROJECT AT END OF PROJECT PERIOD​.  Full Article

Capricor Therapeutics Says FDA Cleared IND Application For CAP-1002
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CAP-1002.CAPRICOR THERAPEUTICS INC - POTENTIAL REGISTRATION TRIAL IN DUCHENNE MUSCULAR DYSTROPHY ON TRACK TO INITIATE IN Q1 OF 2018.CAPRICOR THERAPEUTICS-PLANS TO APPLY FOR REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR CAP-1002 BASED ON UPDATED GUIDANCE RECENTLY ISSUED BY FDA.  Full Article

Capricor Therapeutics reports Q3 loss per share $0.12
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Capricor Therapeutics Inc ::Capricor Therapeutics reports third quarter 2017 financial results and provides update on duchenne muscular dystrophy development program.Q3 loss per share $0.12.  Full Article

Capricor Therapeutics Q2 loss per share $0.26
Tuesday, 16 Aug 2016 

Capricor Therapeutics Inc : Capricor Therapeutics reports second quarter 2016 financial results and provides clinical update . Q2 loss per share $0.26 . Duchenne muscular dystrophy trial on track to report top-line six-month results in Q1 of 2017 .Expects existing cash, cash equivalents, marketable securities will fund research and development programs through Q1 of 2017.  Full Article

BRIEF-Capricor Q4 Earnings Per Share $0.42

* CAPRICOR PRESENTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE UPDATE